A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 16, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q3 FY2026, filed Nov 16, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the PULM SEC filings page.
This page shows Pulmatrix, Inc. (PULM) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Pulmatrix’s latest accounts show a sharply smaller operation still consuming cash, with spending now concentrated outside research.
The net loss of$5.162M nearly matches operating cash flow of-$5.433M , indicating little gap between reported losses and cash use. R&D spending fell from$7.166M in FY2024 to$38K , making the current cost base predominantly administrative rather than development-focused.
Assets fell from
The reported liquidity comparison was 9 months of the latest annual operating outflow, a year-end balance-sheet comparison rather than a forecast. The combination of sharply reduced assets and continued negative operating cash flow shows that the company’s financial scale contracted faster than its cash-consuming operations ended.
Financial Health Signals
We do not publish a peer-relative financial health score for Pulmatrix, Inc., because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.
Pulmatrix, Inc. passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). No profitability signals pass, all 2 leverage/liquidity signals pass.
Pulmatrix, Inc. reported a net loss of $5.2M while operations used $5.4M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Pulmatrix, Inc. reported a net loss of $1.2M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Pulmatrix, Inc. earned -$0.34 per diluted share (EPS) in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q3 2026.
Not reported for Q3 2026.
Cash & Balance Sheet
Pulmatrix, Inc. held $1.4M in cash as of Q3 2026; no long-term debt figure is on record for that period.
Not reported for Q3 2026.
Not reported for Q3 2026.
Margins & Returns
Pulmatrix, Inc.'s quarterly ROE was -90.1% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is down 71.6 percentage points from the same quarter a year earlier. Against the prior quarter it is down 49.6 percentage points.
Not reported for Q3 2026.
Not reported for Q3 2026.
Not reported for Q3 2026.
Capital Allocation
Pulmatrix, Inc. invested $1K in research and development in Q3 2026. This represents a decrease of 87.5% from the same quarter a year earlier. Against the prior quarter it is down 50.0%.
Not reported for Q3 2026.
Not reported for Q3 2026.
PULM Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'25S-4/A | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'24S-4/A |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $3K-99.9% |
| R&D Expenses | $1K-87.5% | $2K-85.7% | $3K-84.2% | N/A | $8K-99.0% | $14K-99.5% | $19K-99.5% | $6K-99.8% |
| SG&A Expenses | $1.2M+42.2% | $1.0M-31.9% | $1.3M-29.5% | $911K-53.3% | $858K-61.2% | $1.5M-23.3% | $1.8M+12.4% | $1.9M+113.9% |
| Operating Income | -$1.2Mn/m | -$1.0Mn/m | -$1.3Mn/m | -$908Kn/m | -$866Kn/m | -$1.5Mn/m | -$1.8M-347.3% | -$2.0Mn/m |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -$2.0Mn/m |
| Income Tax | N/A | N/A | N/A | $0 | $0n/m | $0n/m | $0n/m | N/A |
| Net Income | -$1.2Mn/m | -$1.0Mn/m | -$1.2Mn/m | -$928Kn/m | -$877Kn/m | -$1.5Mn/m | -$1.8M-319.2% | -$2.0Mn/m |
| EPS (Basic) | -$0.34n/m | -$0.29n/m | -$0.32n/m | -$0.25n/m | -$0.24n/m | -$0.42n/m | -$0.50-317.4% | -$0.55n/m |
| EPS (Diluted) | -$0.34n/m | -$0.29n/m | -$0.32n/m | -$0.25n/m | -$0.24n/m | -$0.42n/m | -$0.50-317.4% | -$0.55n/m |
| Diluted Shares (Avg) | 4M0.0% | 4M0.0% | 4M0.0% | N/A | 4M0.0% | 4M0.0% | 4M0.0% | N/A |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense.
PULM Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'25S-4/A | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'24S-4/A |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $2.4M-52.6% | $3.2M-47.2% | $4.5M-44.2% | $4.1M-58.4% | $5.0M-56.7% | $6.2M-61.0% | $8.1M-73.5% | $9.9M-70.7% |
| Current Assets | $2.4M-52.6% | $3.2M-47.3% | $4.5M-44.2% | $4.1M-58.4% | $5.0M-56.6% | $6.1M-60.7% | $8.0M-54.3% | $9.9M-52.4% |
| Cash & Equivalents | $1.4M-70.8% | $2.2M-62.8% | $3.3M-56.9% | $4.1M-57.1% | $4.8M-55.5% | $5.8M-52.9% | $7.7M-52.7% | $9.5M-50.3% |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | $16K-97.2% | N/A |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Total Liabilities | $1.0M+308.4% | $689K+25.7% | $905K+0.1% | $329K-67.0% | $249K-57.8% | $548K-77.8% | $904K-92.1% | $996K-93.8% |
| Current Liabilities | $1.0M+308.4% | $689K+25.7% | $905K+0.2% | $329K-64.6% | $249K-57.8% | $548K-77.8% | $903K-71.3% | $929K-76.2% |
| Non-Current Liabilities | $0n/m | $0n/m | $0-100.0% | $0-100.0% | $0n/m | $0n/m | $1K-100.0% | $67K-99.4% |
| Total Equity | $1.3M-71.6% | $2.6M-54.4% | $3.6M-49.8% | $3.8M-57.4% | $4.7M-56.7% | $5.6M-57.9% | $7.1M-62.4% | $8.9M-50.3% |
| Retained Earnings | -$305.7Mn/m | -$304.5Mn/m | -$303.5Mn/m | -$302.3Mn/m | -$301.4Mn/m | -$300.5Mn/m | -$299.0Mn/m | -$297.2Mn/m |
Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.
PULM Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'25S-4/A | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'24S-4/A |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$770Kn/m | -$1.1Mn/m | -$1.1Mn/m | -$706Kn/m | -$1.0Mn/m | -$1.9Mn/m | -$1.8Mn/m | -$1.3Mn/m |
| Depreciation & Amortization | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0-100.0% |
| Stock-Based Compensation | $2K-66.7% | $2K-66.7% | $3K-62.5% | N/A | $6K-97.0% | $6K-94.2% | $8K-96.0% | N/A |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0-100.0% |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -$1.3Mn/m |
| Investing Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0n/m |
| Financing Cash Flow | $0 | -$50K | $1.0M | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
PULM Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'25S-4/A | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'24S-4/A |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -65066.7% |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -66200.0% |
| Return on Equity | -90.1%-71.6pp | -40.5%-12.9pp | -32.6%-7.3pp | -24.4%-2.2pp | -18.5%+5.2pp | -27.6%+16.0pp | -25.3%-29.6pp | -22.2%-10.6pp |
| Return on Assets | -51.3%-33.7pp | -31.9%-6.7pp | -26.1%-3.6pp | -22.4%-2.5pp | -17.6%+4.9pp | -25.2%+11.6pp | -22.5%-25.2pp | -20.0%-13.8pp |
| Current Ratio | 2.32-17.7x | 4.70-6.5x | 4.96-3.9x | 12.55+1.9x | 19.97+0.6x | 11.21+4.9x | 8.90+3.3x | 10.68+5.3x |
| Liabilities-to-Equity | 0.76+0.7x | 0.27+0.2x | 0.25+0.1x | 0.090.0x | 0.050.0x | 0.10-0.1x | 0.13-0.5x | 0.11-0.8x |
| Asset Turnover | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00-0.1x |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -42033.3% |
Not reported in any period shown, so not listed: Gross Margin, Debt-to-Equity.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Pulmatrix, Inc. PULM | FY2025 | N/A | -$5.2M | N/A | $4.9M | — |
| Kiora Pharmaceuticals, Inc. KPRX | FY2025 | $0 | -$10.8M | N/A | $4.3M | — |
| Processa Pharmaceuticals, Inc. PCSA | FY2025 | N/A | -$13.6M | N/A | $4.8M | — |
| Skye Bioscience, Inc. SKYE | FY2025 | N/A | -$55.9M | N/A | $4.7M | — |
| Can-Fite BioPharma Ltd. CANF | FY2025 | $405K | -$9.8M | N/A | $4.7M | — |
| Silo Pharma, Inc. SILO | FY2025 | $72K | -$4.2M | N/A | $3.7M | — |
Where Pulmatrix, Inc. Ranks
Frequently Asked Questions
No, Pulmatrix, Inc. (PULM) reported a net loss of $4.3M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net loss of $5.2M.
Pulmatrix, Inc. (PULM) has a return on equity of -135.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
Pulmatrix, Inc. (PULM) recorded an outflow of $5.4M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
Pulmatrix, Inc. (PULM) had $4.1M in total assets as of fiscal year 2025, including both current and long-term assets.
Pulmatrix, Inc. (PULM) invested $38K in research and development during fiscal year 2025.
Pulmatrix, Inc. (PULM) had a current ratio of 12.55 as of fiscal year 2025, which is generally considered healthy.
Pulmatrix, Inc. (PULM) had a liabilities-to-equity ratio of 0.09 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.
Pulmatrix, Inc. (PULM) had a return on assets of -124.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
Pulmatrix, Inc. (PULM) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $4.9M as of Nov 16, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Pulmatrix, Inc. (PULM) has no price-to-sales ratio at the moment: no full year of revenue reported yet. The market capitalization is $4.9M as of Nov 16, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
At the end of fiscal year 2025, Pulmatrix, Inc. (PULM) held $4.1M in cash, cash equivalents and investments, and reported an operating cash outflow of $5.4M over that year. Dividing the one by the other, the reported balance equals about 9 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Pulmatrix, Inc. (PULM) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Pulmatrix, Inc. (PULM) reported a net loss of $5.2M while operations used $5.4M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.